Specialty Pharmacy Continuum4 New Priorities Set For Specialty Pharmacy Accreditation at AXS26

🎓 Expert Commentary / Peer Perspective

Specialty pharmacies face distinct accreditation decisions, not a single new four-part mandate. The article reports annual in-person DMEPOS surveys under 2026 requirements, while pharmacy accreditation retains its existing three-year cycle. Separately, accreditors describe AI oversight modules, revised oncology dispensing materials, and an immunoglobulin therapy distinction. These developments affect survey preparation, staff competencies, and potential network access. However, the report does not reproduce governing requirements, establish universal applicability, or quantify implementation costs. The DMEPOS scope and effective timing require primary-source confirmation.

Professional Impact

• AI oversight: URAC describes separate developer and user modules addressing system validation, patient-population suitability, and responsible-use processes.
• Oncology dispensing: NCODA reports alignment with updated ASCO–NCODA standards; accreditation does not automatically secure payer-network participation.
• Immunoglobulin services: ACHC’s distinction emphasizes certified personnel and mentoring; it is not presented as mandatory for every infusion pharmacy.
• DMEPOS surveys: The article distinguishes annual in-person DMEPOS reviews from the pharmacy accreditation cycle, creating separate preparation and resource demands.
• Evidence limits: Claims of better adherence, lower costs, and improved care lack sufficient study details or comparative results for independent appraisal.

Action Items

• Verify DMEPOS applicability, exemptions, effective dates, and survey expectations against official requirements and the organization’s accreditor.
• Map applicable accreditation criteria to existing policies, documentation, staff competencies, and quality-management processes.
• Review AI governance responsibilities separately for internally developed tools and externally acquired systems.
• Confirm payer and limited-distribution network recognition before assuming accreditation will expand dispensing access.
• Evaluate survey costs and service-line implications without treating discontinuation of DMEPOS services as an inevitable response.